<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diagn Pathol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diagn Pathol</journal-id>
      <journal-title-group>
        <journal-title>Diagnostic Pathology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1746-1596</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27770806</article-id>
      <article-id pub-id-type="pmc">5075201</article-id>
      <article-id pub-id-type="publisher-id">554</article-id>
      <article-id pub-id-type="doi">10.1186/s13000-016-0554-7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Rapid growth of mitotically active cellular fibroma of the ovary: a case report and review of the literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Matsuda</surname>
            <given-names>Katsuya</given-names>
          </name>
          <address>
            <phone>+81-95-819-7107</phone>
            <email>katsuya@nagasaki-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tateishi</surname>
            <given-names>Seiko</given-names>
          </name>
          <address>
            <email>Seiko_miffy@yahoo.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Akazawa</surname>
            <given-names>Yuko</given-names>
          </name>
          <address>
            <email>akazaway@nagasaki-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kinoshita</surname>
            <given-names>Akira</given-names>
          </name>
          <address>
            <email>akino@nagasaki-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yoshida</surname>
            <given-names>Shiko</given-names>
          </name>
          <address>
            <email>shikoyoshida@yahoo.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Morisaki</surname>
            <given-names>Sachiko</given-names>
          </name>
          <address>
            <email>chonnbi@nifty.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fukushima</surname>
            <given-names>Ai</given-names>
          </name>
          <address>
            <email>ai.ai.ai1220@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsuwaki</surname>
            <given-names>Takahiro</given-names>
          </name>
          <address>
            <email>matsuwaki-takahiro@isahaya.jcho.go.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yoshiura</surname>
            <given-names>Koh-Ichiro</given-names>
          </name>
          <address>
            <email>kyoshi@nagasaki-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakashima</surname>
            <given-names>Masahiro</given-names>
          </name>
          <address>
            <email>moemoe@nagasaki-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Departments of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523 Japan </aff>
        <aff id="Aff2"><label>2</label>Department of Obstetrics and Gynecology, Japan Community Health Care Organization, Isahaya General Hospital, Isahaya, Japan </aff>
        <aff id="Aff3"><label>3</label>Department of Gastroenterology and Hepatology, Nagasaki University Hospital, Nagasaki, Japan </aff>
        <aff id="Aff4"><label>4</label>Department of Human Genetics, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>22</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>11</volume>
      <elocation-id>101</elocation-id>
      <history>
        <date date-type="received">
          <day>5</day>
          <month>8</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>10</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s). 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Mitotically active cellular fibroma (MACF) of the ovary, characterized by relatively high mitotic activity without severe atypia, represents a relatively new disease entity. MACF is categorized as a benign ovarian tumor. However, due to a limited number of case reports, its clinical and pathological features and optimum management remains largely undetermined. Herein, we report on a rare case of MACF that grew rapidly in size and was diagnosed on detailed pathological examination.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 44-year-old Japanese woman, who detected a myoma-like lesion 1-year earlier, was referred to our hospital when the follow-up examination demonstrated that the mass had increased in size. Magnetic resonance imaging revealed a T1 isointense and T2 hyperintense tumor (11&#xA0;cm in diameter) in the right pelvic cavity. Laparoscopy confirmed the presence of a right ovarian tumor and laparoscopic right adnexectomy was performed. The tumor cells consisted of dense cellular proliferations of spindle fibroblast-like cells without significant cytological atypia. The mitotic activity index was estimated at &gt;15 mitotic figures per 10 high-power fields. Reticulin staining and <italic>FOXL2</italic> mutation analysis excluded the possibility of an adult granulosa cell tumor, and the patient was diagnosed with a MACF of the ovary.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>To the best of our knowledge, we are the first to report on a case of rapid growth of a MACF of the ovary during follow-up. When an increase in the size of a solid ovarian mass is detected, a MACF should be considered as a differential diagnosis.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Case report</kwd>
        <kwd>Mitotically active cellular fibroma</kwd>
        <kwd>Preoperative diagnosis</kwd>
        <kwd>Rapid growth</kwd>
        <kwd><italic>FOXL2</italic> analysis</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Ovarian fibrous tumors were previously classified as benign fibromas or malignant fibrosarcomas, according to the World Health Organization&#x2019;s classification of tumors of the breast &amp; Female Genital Origans [<xref ref-type="bibr" rid="CR1">1</xref>]. Ovarian cellular fibromas were defined as having a mitotic figure of &lt;3 per 10 high-power fields without severe nuclear atypia, and fibrosarcomas were defined as having a mitotic figure of &#x2265;4 per 10 high-power fields with severe nuclear atypia [<xref ref-type="bibr" rid="CR1">1</xref>]. Generally, the prognosis of patients with fibrosarcomas is extremely poor [<xref ref-type="bibr" rid="CR2">2</xref>]. However, there have been a minority of cases where the patient was categorized as having fibrosarcoma with mild nuclear atypia, despite a high mitotic activity. These patients were associated with a relatively favorable prognosis [<xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR8">8</xref>]. In 2006, Irving et al. [<xref ref-type="bibr" rid="CR9">9</xref>] defined these types of tumors as mitotically active cellular fibromas (MACFs), thus, distinguishing them from fibrosarcomas. Accordingly, MACFs have now been included under the heading of fibromas in the 2014 World Health Organization classification system [<xref ref-type="bibr" rid="CR10">10</xref>]. MACFs are defined as having a mitotic figure of &lt;3 per 10 high-power fields without severe nuclear atypia and fibrosarcomas are defined as having a mitotic figure of &#x2265;4 per 10 high-power fields with severe nuclear atypia [<xref ref-type="bibr" rid="CR10">10</xref>]. Several case reports have been published since MACFs were defined [<xref ref-type="bibr" rid="CR11">11</xref>&#x2013;<xref ref-type="bibr" rid="CR16">16</xref>]. MACFs are associated with a more favorable prognosis than fibrosarcomas, with limited data on long-term survival rates available [<xref ref-type="bibr" rid="CR17">17</xref>]. However, the natural history of MACFs is still largely unknown and suitable guidelines for diagnosing and treating this condition are lacking.</p>
      <p>Herein, we report on the clinical and histopathological characteristics of a rare case of rapid growth of a MACF of the ovary that almost doubled in size during a 1-year follow-up period and provide a review of the literature.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 44-year-old Japanese woman underwent a medical examination for health check reasons at her local hospital. An ultrasound scan revealed a uterine myoma-like lesion, 5.9&#xA0;cm in diameter. The patient revisited the hospital 12-months later for a follow-up examination. In that time, the lesion had increased to approximately twice its size. The patient was referred to our clinic for a detailed examination. At the first internal examination, the body of the uterus was enlarged to the size of a newborn head; cervical and vaginal discharge was unremarkable. The adnexa were not palpable on both sides. The patient&#x2019;s blood test results were normal. Transvaginal ultrasonography detected an isoechoic solid mass with an ill-defined boundary between the lesion and the uterus (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>). A tumor, 110&#x2009;&#xD7;&#x2009;90&#x2009;&#xD7;&#x2009;80&#xA0;mm in size, was revealed in the right pelvic cavity by magnetic resonance imaging. The tumor exhibited a slightly lobular pattern with smooth margins. The internal mass had a density similar to that of myometrium on abdominal, T1-weighted magnetic resonance imaging and a low density on T2-weighted magnetic resonance imaging in the horizontal plane (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>). Several flow void regions (a bridging vascular sign) were detected between the lesion and the uterus. These findings suggested a subserous myoma. However, the continuity of the lesion and the uterus was unclear. Since we were unable to identify the right ovary, a fibroma/thecoma of the right ovary was considered as a differential diagnosis (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c</xref>). The left ovary did not exhibit any abnormalities. At this point, a preliminary clinical diagnosis of subserous myoma was made and a laparoscopic myomectomy was planned. The laparoscopic findings demonstrated a 10-cm right ovarian mass without intra-abdominal adhesion or rupture of the tumor. The uterus and left appendages were normal in size (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). A laparoscopic right adnexectomy was subsequently performed. The ascitic fluid was serous, and the cytological evaluation was negative.<fig id="Fig1"><label>Fig. 1</label><caption><p>Preoperative transvaginal ultrasonography (<bold>a</bold>) detected an isoechoic solid mass in the right pelvic cavity (approximately 10&#xA0;cm in size) with an ill-defined boundary between the lesion and the uterus, and T2-weighted magnetic resonance imaging of the ovarian tumor in (<bold>b</bold>) the horizontal and (<bold>c</bold>) the sagittal planes</p></caption><graphic xlink:href="13000_2016_554_Fig1_HTML" id="MO1"/></fig>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Laparoscopic findings. The uterus was of a normal size and the mass was a right ovarian tumor</p></caption><graphic xlink:href="13000_2016_554_Fig2_HTML" id="MO2"/></fig>
</p>
      <p>Macroscopically, the cut surface of the tumor was homogeneous and solid in appearance with a yellowish-white pigment. Necrosis and hemorrhage were absent within the tumor (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3a, b</xref>). Microscopic images are depicted in Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4a&#x2013;d</xref>. The capsule of the tumor was intact without necrosis and hemorrhage (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4a</xref>). The tumor cells consisted of dense cellular proliferations of spindle fibroblast-like cells, arranged in a fascicular structure, without significant cytological atypia (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4b</xref>). In addition, a portion of the tumor cells proliferated in a trabecular pattern and a collagen band was distributed around the stroma (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4c</xref>). The tumor was composed of cells with ovoid to spindle-shaped nuclei and a scant cytoplasm. Some of the nuclei had a nuclear groove. No severe cytological atypia was detected. The mitotic activity index was estimated at &gt;15 mitotic figures per 10 high-power fields (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4d</xref>). Pathological differential diagnoses included a cellular fibroma, fibrosarcoma and adult granulosa cell tumor (AGCT).<fig id="Fig3"><label>Fig. 3</label><caption><p>Macroscopic image of the right ovarian tumor. The cut surface of the tumor was homogeneous and solid in appearance with a yellowish-white pigment</p></caption><graphic xlink:href="13000_2016_554_Fig3_HTML" id="MO3"/></fig>
<fig id="Fig4"><label>Fig. 4</label><caption><p>Histopathological findings of the right ovarian tumor. <bold>a</bold> The capsule of the tumor was intact without necrosis and hemorrhage; (<bold>b</bold>) dense cellular proliferations of spindle fibroblast-like cells, arranged in a fascicular structure with ovoid to spindle-shaped nuclei and a scant cytoplasm, and (<bold>c</bold>) tumor cell proliferations in a trabecular pattern with a collagen band distributed around the stroma; and (<bold>d</bold>) absence of significant cytological atypia. The mitotic activity index was estimated at &gt;15 mitotic figures per 10 high-power fields (hematoxylin and eosin staining; original magnification [<bold>a</bold>]&#x2009;&#xD7;&#x2009;20, [<bold>b</bold>, <bold>c</bold>]&#x2009;&#xD7;&#x2009;100, and [<bold>d</bold>]&#x2009;&#xD7;&#x2009;400)</p></caption><graphic xlink:href="13000_2016_554_Fig4_HTML" id="MO4"/></fig>
</p>
      <p>Immunohistochemical staining was positive for vimentin, muscle-specific actin, alpha-smooth muscle actin, alpha-inhibin and progesterone receptor (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5a&#x2013;e</xref>), and negative for calretinin, epithelial membrane antigen, desmin, estrogen receptor, CD10, CD99, chromogranin A, synaptophysin and tumor protein p53. The Ki-67/MIB-1 labeling index was 9.5&#xA0;% (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5f</xref>). Reticulin staining showed reticular fibers surrounding each cell (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5g</xref>). This was not a typical feature of AGCT. We further analyzed genomic DNA (isolated from formalin-fixed, paraffin-embedded tumor tissue sections) for a <italic>FOXL2</italic> c.402C&#x2009;&gt;&#x2009;G (p.C134W) point mutation that is observed in the majority of AGCT patients [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. The <italic>FOXL2</italic> mutation was detected in the AGCT case used as a positive control, but was absent from our case and the negative control (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>). Because necrosis and hemorrhage were not detected macro- or microscopically, a fibrosarcoma was ruled out. After performing the differential diagnoses outlined above, a final diagnosis of MACF was confirmed. Having obtained written informed consent, we evaluated the patient&#x2019;s risk of recurrence. Based on our recommendation and the preference of the patient, we performed radical surgery (simple hysterectomy, left adnexectomy and omentectomy). The patient is undergoing regular follow-up. Recurrence of the tumor has not been observed in the 2-year postsurgical period.<fig id="Fig5"><label>Fig. 5</label><caption><p>Immunohistochemical analysis of the right ovarian tumor exhibiting positivity for (<bold>a</bold>) vimentin, (<bold>b</bold>) muscle-specific actin, (<bold>c</bold>) alpha-smooth muscle actin, (<bold>d</bold>) alpha-inhibin and (<bold>e</bold>) estrogen receptor. <bold>f</bold> The Ki-67/MIB-1 labeling index was 9.5&#xA0;% (original magnification&#x2009;&#xD7;&#x2009;200). <bold>g</bold> Reticulin staining showed reticular fibers surrounding each tumor cell (original magnification&#x2009;&#xD7;&#x2009;100)</p></caption><graphic xlink:href="13000_2016_554_Fig5_HTML" id="MO5"/></fig>
<fig id="Fig6"><label>Fig. 6</label><caption><p>Analysis of a c.402C&#x2009;&gt;&#x2009;G point mutation in the <italic>FOXL2</italic> gene in (<bold>a</bold>) the normal control (<italic>negative; blue circle</italic>), (<bold>b</bold>) the adult granulosa cell tumor patient used as a positive control (<italic>positive; red circle</italic>), and (<bold>c</bold>) our patient with rapid growth of mitotically active cellular fibroma (<italic>negative; blue circle</italic>)</p></caption><graphic xlink:href="13000_2016_554_Fig6_HTML" id="MO6"/></fig>
</p>
    </sec>
    <sec id="Sec3">
      <title>Discussion</title>
      <p>MACF was first defined by Irving et al. [<xref ref-type="bibr" rid="CR9">9</xref>] in 2006, based on a review of 75 cellular fibroma cases. The authors reported that the majority of MACF patients have a good clinical course compared to fibrosarcoma patients. However, there was a case where death was associated with peritoneal adhesion and capsule rupture and Irving et al. [<xref ref-type="bibr" rid="CR9">9</xref>] could not necessarily conclude it to be a benign tumor. Therefore, pathological differential diagnoses of ovarian fibromatous tumors (including cellular fibroma, MACF and fibrosarcoma) are important since they influence decision-making, as well as, the prognosis of different treatment strategies.</p>
      <p>Only six MACF cases have been reported since a definition of MACF was established in 2006 (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). The natural history of MACF is still largely unknown. Five (83.3&#xA0;%) of these recently reported cases were given a diagnosis of ovarian tumor. However, there has not been a single case where a diagnosis of MACF was confirmed preoperatively. Because there are no clinically useful serum tumor markers for MACF, or characteristic imaging findings, a preoperative diagnosis of MACF remains challenging at this time. There was a case report where the size of the tumor did not change during 10-years of follow-up [<xref ref-type="bibr" rid="CR16">16</xref>]. In contrast, there was also a case report where a recurrent tumor, 8&#xA0;cm in diameter, was detected in the pararectal region after 6&#xA0;months of follow-up. In our case, a mass of 6&#xA0;cm was found to have almost doubled in size, to 10&#xA0;cm, during a 1-year follow-up period. Thus, when a solid ovarian tumor increases in size, even though malignancy findings are not found considering preoperative serum tumor marker values or imaging findings, MACF may well be included as a candidate for the differential diagnosis. In the 6 case reports published since the paper by Irving et al. [<xref ref-type="bibr" rid="CR9">9</xref>], 5 patients (83.3&#xA0;%) underwent open surgery, including a unilateral salpingo-oophorectomy in 2 patients [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>] and a radical operation (bilateral oophorectomy and hysterectomy) in 3 patients [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. One patient treated with laparoscopic oophorectomy was reported by Yamada et al. [<xref ref-type="bibr" rid="CR16">16</xref>] in 2015. However, because the follow-up period remains limited, the long-term prognosis has yet to be determined. No standard treatment for MACF currently exists, although overtreatment should be avoided in women requiring preservation of fecundity [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Zong et al. [<xref ref-type="bibr" rid="CR15">15</xref>] suggested that other risk factors, such as tumor size, growth rate and Ki-67 positivity, should be considered. As our case grew rapidly, the tumor size was relatively large, and the patient did not wish to conceive, we concluded that radical surgery was a reasonable option. Moreover, because there were no signs of recurrence, complete resection was not necessary for administering chemotherapy for the tumor associated with capsule rupture and peritoneal adhesion [<xref ref-type="bibr" rid="CR15">15</xref>]. In contrast, there was a case where recurrence occurred 5-years after surgery [<xref ref-type="bibr" rid="CR12">12</xref>]. Therefore, we believe long-term follow-up is necessary.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Literature review of reported cases of mitotically active cellular fibroma</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th/><th/><th/><th/><th/><th/><th colspan="6">Immunohistochemistry</th><th/></tr><tr><th>Author(s)</th><th>Age (y)</th><th>Size (cm)</th><th>PD</th><th>Rupture</th><th>Adhesion</th><th>Surgery</th><th>Mitoses (MF/10 HRP)</th><th>Ki-67 PI</th><th>Vimentin</th><th>SMA</th><th>&#x3B1;-inhibin</th><th>Calretinin</th><th>EMA</th><th>Prognosis</th></tr></thead><tbody><tr><td>Kaku et al. [<xref ref-type="bibr" rid="CR11">11</xref>]</td><td>32</td><td>6.6&#x2009;&#xD7;&#x2009;6.0&#x2009;&#xD7;&#x2009;4.4</td><td>OT</td><td>&#x2013;</td><td>&#x2013;</td><td>LSO</td><td>17</td><td>50</td><td>+</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>12&#xA0;month NED</td></tr><tr><td rowspan="3">Bucella et al. [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td rowspan="3">65</td><td>10.0 (First)</td><td rowspan="3">OT</td><td rowspan="3">&#x2013;</td><td rowspan="3">&#x2013;</td><td rowspan="3">TAH, BSO</td><td rowspan="3">4</td><td rowspan="3">9</td><td rowspan="3">+</td><td rowspan="3">ND</td><td rowspan="3">Focal+</td><td rowspan="3">ND</td><td rowspan="3">ND</td><td rowspan="3">Recurrence twice NED</td></tr><tr><td>12.0 (Second)</td></tr><tr><td>8.0 (Third)</td></tr><tr><td>Monteiro et al. [<xref ref-type="bibr" rid="CR13">13</xref>]</td><td>13</td><td>19.0&#x2009;&#xD7;&#x2009;15.0&#x2009;&#xD7;&#x2009;12.0</td><td>OT</td><td>&#x2013;</td><td>Omentum</td><td>RSO, OMT</td><td>5&#x2013;7</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>36&#xA0;month NED</td></tr><tr><td>Wu et al. [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td>76</td><td>9.0&#x2009;&#xD7;&#x2009;6.0&#x2009;&#xD7;&#x2009;5.0</td><td>PM</td><td>&#x2013;</td><td>&#x2013;</td><td>TAH, BSO</td><td>5&#x2013;9</td><td>&gt;10</td><td>+</td><td>ND</td><td>+</td><td>&#x2013;</td><td>&#x2013;</td><td>ND</td></tr><tr><td>Zong et al. [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td>39</td><td>10.0&#x2009;&#xD7;&#x2009;7.0&#x2009;&#xD7;&#x2009;4.0</td><td>OT</td><td>+</td><td>Left latum &amp; uterus</td><td>TAH, LSO, OMT, AD, LD</td><td>3&#x2013;5</td><td>10</td><td>+</td><td>+</td><td>ND</td><td>ND</td><td>&#x2013;</td><td>66&#xA0;month NED</td></tr><tr><td>Yamada et al. [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td>36</td><td>6.0</td><td>OT</td><td>ND</td><td>&#x2013;</td><td>LS (RSO)</td><td>10</td><td>8.7</td><td>+</td><td>ND</td><td>Focal+</td><td>&#x2013;</td><td>&#x2013;</td><td>6&#xA0;month NED</td></tr><tr><td rowspan="2">Present case</td><td rowspan="2">44</td><td>5.9 (First)</td><td rowspan="2">Myoma</td><td rowspan="2">&#x2013;</td><td rowspan="2">&#x2013;</td><td rowspan="2">LS (First), TAH, LSO, OMT (Second)</td><td rowspan="2">6.7</td><td rowspan="2">9.5</td><td rowspan="2">+</td><td rowspan="2">+</td><td rowspan="2">Focal+</td><td rowspan="2">&#x2013;</td><td rowspan="2">&#x2013;</td><td rowspan="2">26&#xA0;month NED</td></tr><tr><td>11.0 (Second)</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations: &#x3B1;</italic> alpha, <italic>AD</italic> appendectomy, <italic>BSO</italic> bilateral salpingo-oophorectomy, <italic>EMA</italic> epithelial membrane antigen, <italic>HRP</italic> high power field, <italic>LD</italic> lymph node dissection, <italic>LS</italic> laparoscopic surgery, <italic>LSO</italic> left salpingo-oophorectomy, <italic>MF</italic> mitotic figure, <italic>ND</italic> not described, <italic>NED</italic> no evidence of disease, <italic>OMT</italic> omentectomy, <italic>OT</italic> ovarian tumor, <italic>PD</italic> preoperative diagnosis, <italic>PI</italic> proliferative index, <italic>PM</italic> pelvic mass, <italic>RSO</italic> right salpingo-oophorectomy, <italic>SMA</italic> smooth muscle actin, <italic>TAH</italic> total abdominal hysterectomy, <italic>y</italic> year, <italic>+</italic> positive, <italic>&#x2212;</italic> negative</p></table-wrap-foot></table-wrap>
</p>
      <p>MACFs are defined as cellular fibromas with a high mitotic activity index (&#x2265;4 mitotic figures per 10 high-power fields) and mild to moderate nuclear atypia [<xref ref-type="bibr" rid="CR10">10</xref>]. The differential diagnosis with fibrosarcoma is possible for nuclear atypia and the presence of necrosis and hemorrhage. There is a difficult case for the histological differential diagnosis of cellular fibroma and AGCT (especially the diffuse type) [<xref ref-type="bibr" rid="CR20">20</xref>]. Cellular fibromas and AGCTs are represented by the sex cord-stromal tumors [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. However, the majority of borderline malignant sex cord-stromal tumors are AGCTs [<xref ref-type="bibr" rid="CR21">21</xref>]. Therefore, the differential diagnosis with commonly benign cellular fibroma is important.</p>
      <p>The <italic>FOXL2</italic> c.402C&#x2009;&gt;&#x2009;G (p.C134W) point mutation is detected in 95.0&#xA0;% of AGCT patients, especially those with the diffuse type [<xref ref-type="bibr" rid="CR18">18</xref>&#x2013;<xref ref-type="bibr" rid="CR20">20</xref>]. It has been described that this point mutation does not reflect immunohistochemical staining pattern of FOXL2 [<xref ref-type="bibr" rid="CR20">20</xref>]. In addition, the pattern of reticulin staining is different for these disease entities. Thus, combination of <italic>FOXL2</italic> point mutation analysis and reticulin staining can be employed in differential diagnosis of cellular fibroma and AGCT. In this case, we rejected a diagnosis of AGCT based on <italic>FOXL2</italic> mutation analysis and reticulin staining, and confirmed a final diagnosis of MACF.</p>
    </sec>
    <sec id="Sec4">
      <title>Conclusions</title>
      <p>We report our experience of a case of rapid growth of a MACF of the ovary during a 1-year follow-up period. When preoperative serum tumor marker levels and/or imaging findings do not suggest ovarian cancer in instances of rapid growth of a solid ovarian mass, MACF should be considered as a differential diagnosis. Our case and review of the literature suggest that MACF of the ovary may represent a heterogeneous disease entity that requires an accumulation of case reports to establish diagnosis and treatment.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>AGCT</term>
          <def>
            <p>Adult granulosa cell tumor</p>
          </def>
        </def-item>
        <def-item>
          <term>MACF</term>
          <def>
            <p>Mitotically active cellular fibroma</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ack>
      <title>Acknowledgements</title>
      <p>We wish to thank Editage (<ext-link ext-link-type="uri" xlink:href="https://www.editage.jp">https://www.editage.jp</ext-link>) for English language editing.</p>
      <sec id="FPar1">
        <title>Funding</title>
        <p>This research received no specific financial or material support.</p>
      </sec>
      <sec id="FPar2">
        <title>Availability of data and material</title>
        <p>All available data are included in the manuscript and its figures.</p>
      </sec>
      <sec id="FPar3">
        <title>Authors&#x2019; contributions</title>
        <p>KM and ST collected clinical data and drafted the manuscript. YA and MN revised the final version of the manuscript for important intellectual content. KM and MN conducted the pathological evaluation of the specimen and assisted in editing the pathology. KM, AK and KY performed the genetic analysis. ST, SY, SM, AF and TM performed the clinical diagnosis and treatment. All authors read and approved the final version of the manuscript prior to submission.</p>
      </sec>
      <sec id="FPar4">
        <title>Competing interests</title>
        <p>The authors declare that they have no competing interests.</p>
      </sec>
      <sec id="FPar5">
        <title>Consent for publication</title>
        <p>Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the consent form is available on request for review by the Editor of this journal.</p>
      </sec>
      <sec id="FPar6">
        <title>Ethics approval and consent to participate</title>
        <p>Not applicable.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Tavassoli</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Devilee</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <source>WHO classification of tumours pathology &amp; genetics tumours of the breast and female genital organs</source>
          <year>2003</year>
          <publisher-loc>IARC</publisher-loc>
          <publisher-name>Lyon</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Prat</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Scully</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Cellular fibromas and fibrosarcomas of the ovary: a comparative clinicopathologic analysis of seventeen cases</article-title>
          <source>Cancer</source>
          <year>1981</year>
          <volume>47</volume>
          <fpage>2663</fpage>
          <lpage>2670</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(19810601)47:11&lt;2663::AID-CNCR2820471124&gt;3.0.CO;2-V</pub-id>
          <pub-id pub-id-type="pmid">7260859</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Christman</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Ballon</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>Ovarian fibrosarcoma associated with Maffucci&#x2019;s syndrome</article-title>
          <source>Gynecol Oncol</source>
          <year>1990</year>
          <volume>37</volume>
          <fpage>290</fpage>
          <lpage>291</lpage>
          <pub-id pub-id-type="doi">10.1016/0090-8258(90)90350-T</pub-id>
          <pub-id pub-id-type="pmid">2344976</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Chou</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Dai</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Tzeng</surname>
              <given-names>CC</given-names>
            </name>
          </person-group>
          <article-title>Ovarian fibrosarcoma with long-term survival: a case report</article-title>
          <source>Int J Gynecol Cancer</source>
          <year>2001</year>
          <volume>11</volume>
          <fpage>331</fpage>
          <lpage>333</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1525-1438.2001.011004331.x</pub-id>
          <pub-id pub-id-type="pmid">11520377</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kr&#xFC;ger</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>K&#xFC;pker</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Rath</surname>
              <given-names>FW</given-names>
            </name>
            <name>
              <surname>Feller</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Fibrosarcoma associated with a benign cystic teratoma of the ovary</article-title>
          <source>Gynecol Oncol</source>
          <year>2002</year>
          <volume>84</volume>
          <fpage>150</fpage>
          <lpage>154</lpage>
          <pub-id pub-id-type="doi">10.1006/gyno.2001.6408</pub-id>
          <pub-id pub-id-type="pmid">11748992</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cinel</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Taner</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nabaei</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Oguz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>G&#xF6;kmen</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Ovarian fibrosarcoma with five-year survival: a case report</article-title>
          <source>Eur J Gynaecol Oncol</source>
          <year>2002</year>
          <volume>23</volume>
          <fpage>345</fpage>
          <lpage>346</lpage>
          <pub-id pub-id-type="pmid">12214741</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>Q</given-names>
            </name>
          </person-group>
          <article-title>Fibrosarcoma of the ovary arising in a fibrothecomatous tumor with minor sex cord elements. A case report and review of the literature</article-title>
          <source>Arch Pathol Lab Med</source>
          <year>2003</year>
          <volume>127</volume>
          <fpage>81</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="pmid">12521373</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gultekin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dursun</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ozyuncu</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Usubutun</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yuce</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ayhan</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Primary ovarian fibrosarcoma: a case report and review of the literature</article-title>
          <source>Int J Gynecol Cancer</source>
          <year>2005</year>
          <volume>15</volume>
          <fpage>1142</fpage>
          <lpage>1147</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1525-1438.2005.00327.x</pub-id>
          <pub-id pub-id-type="pmid">16343198</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Irving</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Alkushi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Clement</surname>
              <given-names>PB</given-names>
            </name>
          </person-group>
          <article-title>Cellular fibromas of the ovary: a study of 75 cases including 40 mitotically active tumors emphasizing their distinction from fibrosarcoma</article-title>
          <source>Am J Surg Pathol</source>
          <year>2006</year>
          <volume>30</volume>
          <fpage>929</fpage>
          <lpage>938</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-200608000-00001</pub-id>
          <pub-id pub-id-type="pmid">16861962</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Kurman</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Carcangiu</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Herrington</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <source>WHO classification of tumours of female reproductive organs</source>
          <year>2014</year>
          <edition>4</edition>
          <publisher-loc>Lyon</publisher-loc>
          <publisher-name>IARC</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaku</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takeshima</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Akiyama</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Furuta</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hirai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Takizawa</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>A unique fibrous tumor of the ovary: fibrosarcoma or mitotically active cellular fibroma?</article-title>
          <source>Anticancer Res</source>
          <year>2007</year>
          <volume>27</volume>
          <fpage>4365</fpage>
          <lpage>4369</lpage>
          <pub-id pub-id-type="pmid">18214045</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bucella</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Limbosch</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Buxant</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fayt</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Anaf</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Recurrence of mitotically active cellular fibroma of the ovary</article-title>
          <source>Obstet Gynecol Int</source>
          <year>2009</year>
          <pub-id pub-id-type="pmid">19960053</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Monteiro</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Paiva</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Mitotically active cellular ovarian fibroma with Meigs&#x2019; syndrome and elevated CA-125: towards fertility preservation</article-title>
          <source>J Pediatr Adolesc Gynecol</source>
          <year>2012</year>
          <volume>25</volume>
          <fpage>e107</fpage>
          <lpage>e109</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jpag.2012.05.012</pub-id>
          <pub-id pub-id-type="pmid">22980413</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Mitotically active cellular fibroma of the ovary: a case report and a review of the literature</article-title>
          <source>Eur J Gynaecol Oncol</source>
          <year>2014</year>
          <volume>35</volume>
          <fpage>81</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="pmid">24654469</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zong</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Mitotically active cellular fibroma of ovary should be differentiated from fibrosarcoma: a case report and review of literature</article-title>
          <source>Int J Clin Exp Pathol</source>
          <year>2014</year>
          <volume>7</volume>
          <fpage>7578</fpage>
          <lpage>7582</lpage>
          <pub-id pub-id-type="pmid">25550794</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hattori</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Satomi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hirose</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nakai</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Daimon</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mitotically active cellular fibroma of the ovary: a case report and literature review</article-title>
          <source>J Ovarian Res</source>
          <year>2015</year>
          <volume>8</volume>
          <fpage>65</fpage>
          <pub-id pub-id-type="doi">10.1186/s13048-015-0191-x</pub-id>
          <pub-id pub-id-type="pmid">26437718</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choi</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Ha</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>Primary ovarian fibrosarcoma with long-term survival: a report of two cases</article-title>
          <source>J Obstet Gynaecol Res</source>
          <year>2006</year>
          <volume>32</volume>
          <fpage>524</fpage>
          <lpage>528</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1447-0756.2006.00448.x</pub-id>
          <pub-id pub-id-type="pmid">16984523</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shah</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>K&#xF6;bel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Senz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Morin</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Clarke</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Wiegand</surname>
              <given-names>KC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutation of FOXL2 in granulosa-cell tumors of the ovary</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>360</volume>
          <fpage>2719</fpage>
          <lpage>2729</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa0902542</pub-id>
          <pub-id pub-id-type="pmid">19516027</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kommoss</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Anglesio</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Mackenzie</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Senz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines</article-title>
          <source>Mod Pathol</source>
          <year>2013</year>
          <volume>26</volume>
          <fpage>860</fpage>
          <lpage>867</lpage>
          <pub-id pub-id-type="doi">10.1038/modpathol.2012.226</pub-id>
          <pub-id pub-id-type="pmid">23348906</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCluggage</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kommoss</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Huntsman</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Gilks</surname>
              <given-names>CB</given-names>
            </name>
          </person-group>
          <article-title>Ovarian cellular fibromas lack FOXL2 mutations: a useful diagnostic adjunct in the distinction from diffuse adult granulosa cell tumor</article-title>
          <source>Am J Surg Pathol</source>
          <year>2013</year>
          <volume>37</volume>
          <fpage>1450</fpage>
          <lpage>1455</lpage>
          <pub-id pub-id-type="doi">10.1097/PAS.0b013e31828e4f55</pub-id>
          <pub-id pub-id-type="pmid">23774170</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colombo</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Parma</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zanagnolo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Insinga</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Management of ovarian stromal cell tumors</article-title>
          <source>J Clin Oncol</source>
          <year>2007</year>
          <volume>25</volume>
          <fpage>2944</fpage>
          <lpage>2951</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2007.11.1005</pub-id>
          <pub-id pub-id-type="pmid">17617526</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
